Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

Preclinical data on novel NK-Cell engager to be presented at the AACR Annual Meeting 2026

April 13, 2026 – Oncopeptides AB today announces that new preclinical data for its proprietary SPiKE platform has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026. The study, which evaluates a novel NK-cell engager in combination with a NK cell product in multiple myeloma, will be presented as a poster during the congress.

Read more

CEO Sofia Heigis presented at Redeye event Commercialization in Life Science

March 23, 2026 – Oncopeptides’ CEO Sofia Heigis recently presented the company at the Redeye event Commercialization in Life Science. The presentation was followed by a Q&A.

Watch the presentation

Oncopeptalks on real world data and questions from investors

March 20, 2026 – In the latest episode of Oncopeptalks, Sofia Heigis talks more about recent initiatives to strengthen access to real world data in the company’s key markets.

Watch the last episode

Company news

Notice to Annual General Meeting at Oncopeptides AB (publ)

April 16, 2025

The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.

Read more

Oncopeptalks – first order in Italy and Q4 report

March 13, 2025

In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.

Read more

Oncopeptides receives first order of Pepaxti in Italy

March 11, 2025

Read more

Science news

Preclinical data on novel NK-Cell engager to be presented at the AACR Annual Meeting 2026

April 13, 2026

Oncopeptides AB today announces that new preclinical data for its proprietary SPiKE platform has been accepted for presentation at the AACR Annual Meeting 2026.

Read more

Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany

March 16, 2026

Read more

European Journal of Haematology: Real-World Data reinforces Pepaxti’s role in treatment sequencing for multiple myeloma

March 13, 2026

Read more

Investor news

CEO Sofia Heigis presented at Redeye event Commercialization in Life Science

March 23, 2026

Read more

Sofia Heigis presented and interviewed at Stockholm Corporate Finance Life Science Days

March 20, 2026

Read more

Oncopeptalks on real world data and questions from investors

March 20, 2026

Read more

All Company news

All Science news

All Investor news

CEO Sofia Heigis - Oncopeptides AB

Released February 19, 2026

Oncopeptides publishes year-end report 2025

Read report

Download

“Net sales more than doubled in 2025 with 125 percent growth, as glioblastoma program marks strategic pipeline expansion beyond multiple myeloma”

CEO Sofia Heigis

 

See the Webcast

 

 

For further information, please contact:

David Augustsson
Director of IR and Communications
ir@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Interim Report Q1 2026 will be published May 13, 2026

Press release - April 16, 2026

Annual General Meeting in Oncopeptides

Read press release

Latest press releases

All press releases

Upcoming events

2026-04-13 - 2026-05-12

Silent period

Other

2026-04-28

Annual report 2025

none

2026-05-13

Interim Report Q1 2026

Report

Full calendar
Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.

Read more about our history

Released April 28, 2025

Oncopeptides publishes the 2024 Annual Report

Read report

Download

“2024 was a transformative year for Oncopeptides as we continued our journey toward sustainable growth and expanded access to Pepaxti.”

CEO Sofia Heigis

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025

Oncopeptides via e-mail